Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPL39L mRNA | CTD | PMID:22079256 | 1,2-dimethylhydrazine | decreases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of RPL39L mRNA | CTD | PMID:27840820 | 17beta-estradiol | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Estradiol results in decreased expression of RPL39L mRNA | CTD | PMID:23019147 | 17beta-estradiol | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Estradiol results in increased expression of RPL39L mRNA | CTD | PMID:32145629 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to RPL39L promoter] | CTD | PMID:19654925 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of RPL39L mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of RPL39L mRNA | CTD | PMID:21570461 | 2-hydroxypropanoic acid | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of RPL39L mRNA | CTD | PMID:30851411 | aflatoxin B1 | decreases methylation | ISO | RPL39L (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of RPL39L gene | CTD | PMID:27153756 | aldrin | increases expression | EXP | | 6480464 | Aldrin results in increased expression of RPL39L mRNA | CTD | PMID:18579281 | all-trans-retinoic acid | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of RPL39L mRNA | CTD | PMID:21934132 and PMID:33167477 | arsenite(3-) | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | arsenite promotes the reaction [G3BP1 protein binds to RPL39L mRNA] | CTD | PMID:32406909 | benzo[a]pyrene | increases methylation | ISO | RPL39L (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of RPL39L 5' UTR and Benzo(a)pyrene results in increased methylation of RPL39L promoter | CTD | PMID:27901495 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20382639 | benzo[e]pyrene | decreases methylation | ISO | RPL39L (Homo sapiens) | 6480464 | benzo(e)pyrene results in decreased methylation of RPL39L intron | CTD | PMID:30157460 | Benzo[ghi]perylene | decreases expression | EXP | | 6480464 | 1 and 12-benzoperylene results in decreased expression of RPL39L mRNA | CTD | PMID:26377693 | bisphenol A | decreases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of RPL39L mRNA | CTD | PMID:25181051 and PMID:35192832 | bisphenol A | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of RPL39L mRNA | CTD | PMID:29275510 | cadmium atom | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of RPL39L mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of RPL39L mRNA | CTD | PMID:35301059 | carbamazepine | affects expression | ISO | RPL39L (Homo sapiens) | 6480464 | Carbamazepine affects the expression of RPL39L mRNA | CTD | PMID:25979313 | chloroethene | increases expression | EXP | | 6480464 | Vinyl Chloride results in increased expression of RPL39L mRNA | CTD | PMID:18579281 | cobalt dichloride | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | cobaltous chloride results in decreased expression of RPL39L mRNA | CTD | PMID:19320972 and PMID:19376846 | coumestrol | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Coumestrol results in increased expression of RPL39L mRNA | CTD | PMID:19167446 | coumestrol | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPL39L mRNA | CTD | PMID:19167446 | Cuprizon | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Cuprizone results in increased expression of RPL39L mRNA | CTD | PMID:26577399 | dextran sulfate | increases expression | EXP | | 6480464 | Dextran Sulfate results in increased expression of RPL39L mRNA | CTD | PMID:35093514 | dibenz[a,h]anthracene | decreases expression | EXP | | 6480464 | 1 more ... | CTD | PMID:26377693 | diclofenac | increases expression | EXP | | 6480464 | Diclofenac results in increased expression of RPL39L mRNA | CTD | PMID:26934552 | diethylstilbestrol | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Diethylstilbestrol results in increased expression of RPL39L mRNA | CTD | PMID:36653537 | Enterolactone | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPL39L mRNA | CTD | PMID:19167446 | glycidol | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | glycidol results in increased expression of RPL39L mRNA | CTD | PMID:24395379 | indometacin | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Indomethacin results in increased expression of RPL39L mRNA | CTD | PMID:24737281 | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of RPL39L mRNA | CTD | PMID:22609695 | methamphetamine | increases expression | EXP | | 6480464 | Methamphetamine results in increased expression of RPL39L mRNA | CTD | PMID:26307267 | methapyrilene | decreases methylation | ISO | RPL39L (Homo sapiens) | 6480464 | Methapyrilene results in decreased methylation of RPL39L intron | CTD | PMID:30157460 | methyl methanesulfonate | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of RPL39L mRNA | CTD | PMID:23649840 | methylisothiazolinone | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | 2-methyl-4-isothiazolin-3-one results in decreased expression of RPL39L mRNA | CTD | PMID:31629900 | oxaliplatin | multiple interactions | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of RPL39L mRNA and [Topotecan co-treated with oxaliplatin] results in increased expression of RPL39L mRNA | CTD | PMID:25729387 | oxaliplatin | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | oxaliplatin results in increased expression of RPL39L mRNA | CTD | PMID:25729387 | paracetamol | decreases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of RPL39L mRNA | CTD | PMID:33387578 | picoxystrobin | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | picoxystrobin results in increased expression of RPL39L mRNA | CTD | PMID:33512557 | potassium chromate | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of RPL39L mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | RPL39L (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPL39L mRNA | CTD | PMID:22079256 | rac-lactic acid | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Lactic Acid results in decreased expression of RPL39L mRNA | CTD | PMID:30851411 | sodium arsenite | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of RPL39L mRNA | CTD | PMID:34032870 | sunitinib | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of RPL39L mRNA | CTD | PMID:31533062 | temozolomide | decreases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Temozolomide results in decreased expression of RPL39L mRNA | CTD | PMID:31758290 | topotecan | multiple interactions | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of RPL39L mRNA and [Topotecan co-treated with oxaliplatin] results in increased expression of RPL39L mRNA | CTD | PMID:25729387 | topotecan | increases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Topotecan results in increased expression of RPL39L mRNA | CTD | PMID:25729387 | trichloroethene | decreases expression | ISO | Rpl39l1 (Rattus norvegicus) | 6480464 | Trichloroethylene results in decreased expression of RPL39L mRNA | CTD | PMID:33387578 | triptonide | increases expression | EXP | | 6480464 | triptonide results in increased expression of RPL39L mRNA | CTD | PMID:33045310 | ursodeoxycholic acid | affects expression | ISO | RPL39L (Homo sapiens) | 6480464 | Ursodeoxycholic Acid affects the expression of RPL39L mRNA | CTD | PMID:18422935 | valproic acid | increases expression | ISO | RPL39L (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of RPL39L mRNA | CTD | PMID:29154799 | valproic acid | affects expression | ISO | RPL39L (Homo sapiens) | 6480464 | Valproic Acid affects the expression of RPL39L mRNA | CTD | PMID:25979313 | |